JY
STOK icon

Jeff Yass’s Stoke Therapeutics STOK Stock Holding History

Jeff Yass’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$736K Buy
22,500
+600
+3% +$19.3K ﹤0.01% 8981
2026
Q1 		$713K Sell
21,900
-23,800
-52% -$781K ﹤0.01% 8772
2025
Q4 		$1.45M Buy
+45,700
New +$1.37M ﹤0.01% 6333
2024
Q2 		– Sell
-10,100
Closed -$136K – 13195
2024
Q1 		$136K Buy
+10,100
New +$61.2K ﹤0.01% 10981
2021
Q3 		– Sell
-37,300
Closed -$1.26M – 13532
2021
Q2 		$1.26M Buy
37,300
+19,900
+114% +$703K ﹤0.01% 7120
2021
Q1 		$676K Buy
17,400
+3,400
+24% +$194K ﹤0.01% 8759
2020
Q4 		$867K Buy
14,000
+1,700
+14% +$77.9K ﹤0.01% 7048
2020
Q3 		$412K Sell
12,300
-2,000
-14% -$57.1K ﹤0.01% 8080
2020
Q2 		$341K Buy
+14,300
New +$339K ﹤0.01% 8130

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jeff Yass's STOK Position: Q2 2026 in Review

Jeff Yass sold out of Stoke Therapeutics (STOK) in Q2 2026, closing a stake of 57,291 shares — an estimated $1.84M sold.

Jeff Yass first reported a position in STOK in Q1 2020 and held it in 21 quarters. The position peaked at $2.07M in Q4 2024. 196 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Jeff Yass reported no remaining Stoke Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 57,291 Stoke Therapeutics shares in Q2 2026, an estimated $1.84M.
  • Jeff Yass first reported a position in Stoke Therapeutics in Q1 2020 and held it in 21 quarters.
  • Jeff Yass's Stoke Therapeutics position peaked at $2.07M in Q4 2024.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.